Overview on the use of recombinant factor VIIa in obstetrics and gynecology

References

• AbouZahr C, Wardlaw T. Maternal Mortality in 2000: Estimates developed by WHO, UNICEF, UNFPA. WHO, Geneva, Switzerland (2004).
   Google Scholar
• Mousa HA, Walkinshaw S. Major postpartum haemorrhage. Curr. Opin. Obstet. Gynecol.13(6), 595–603 (2001).
   PubMed Web of Science ®Google Scholar
• Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit. Care Med.33(4), 883–890 (2005).
   PubMed Web of Science ®Google Scholar
• Rizoli SB, Chughtai T. The emerging role of recombinant activated factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. Expert. Opin. Biol. Ther.6(1), 73–81 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA295(3), 293–298 (2006).
   PubMed Web of Science ®Google Scholar
• Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet354(9193), 1879 (1999).
   PubMed Web of Science ®Google Scholar
• Committee on Trauma. Shock. In: American College of Surgeons, Advanced Trauma Life Support – Student Course Manual. IL, USA, 69–102 (2004).
   Google Scholar
• Sauaia A, Moore FA, Moore EE et al. Epidemiology of trauma deaths: a reassessment. J. Trauma38(2), 185–193 (1995).
   PubMed Web of Science ®Google Scholar
• Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J. Trauma55(5), 886–891 (2003).
   PubMedGoogle Scholar
• Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet367(9516), 1066–1674 (2006).
   PubMed Web of Science ®Google Scholar
• Berg CJ, Atrash HK, Koonin LM, T ucker M. Pregnancy-related mortality in the United States, 1987–1990. Obstet. Gynecol.88(2), 161–167 (1996).
   PubMed Web of Science ®Google Scholar
• Dildy GA 3rd. Postpartum hemorrhage: new management options. Clin. Obstet. Gynecol.45(2), 330–344 (2002).
   PubMed Web of Science ®Google Scholar
• Pahlavan P, Nezhat C, Nezhat C. Hemorrhage in obstetrics and gynecology. Curr. Opin. Obstet. Gynecol.13(4), 419–424 (2001).
   PubMed Web of Science ®Google Scholar
• Uszynski W, Uszynski M. Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks. Ginekol. Pol.75(12), 971–978 (2004).
   PubMedGoogle Scholar
• Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br. J. Anaesth.94(5), 592–595 (2005).
   PubMed Web of Science ®Google Scholar
• Yucel O, Ozdemir I, Yucel N, Somunkiran A. Emergency peripartum hysterectomy: a 9-year review. Arch. Gynecol. Obstet.274(2), 84–87 (2006).
   PubMedGoogle Scholar
• Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet. Gynecol.107(4), 927–941 (2006).
   PubMed Web of Science ®Google Scholar
• Comstock CH, Love JJ Jr, Bronsteen RA et al. Sonographic detection of placenta accreta in the second and third trimesters of pregnancy. Am. J. Obstet. Gynecol.190(4), 1135–1140 (2004).
   PubMed Web of Science ®Google Scholar
• O’Brien JM, Barton JR. Controversies with the diagnosis and management of HELLP syndrome. Clin. Obstet. Gynecol.48(2), 460–477 (2005).
   PubMed Web of Science ®Google Scholar
• Padden MO. HELLP syndrome: recognition and perinatal management. Am. Fam. Physician60(3), 829–836 (1999).
   PubMed Web of Science ®Google Scholar
• Klapholz H. Blood transfusion in contemporary obstetric practice. Obstet. Gynecol.75(6), 940–943 (1990).
   PubMed Web of Science ®Google Scholar
• Andres RL, Piacquadio KM, Resnik R. A reappraisal of the need for autologous blood donation in the obstetric patient. Am. J. Obstet. Gynecol.163(5 Pt 1), 1551–1553 (1990).
   PubMed Web of Science ®Google Scholar
• Dickason LA, Dinsmoor MJ. Red blood cell transfusion and cesarean section. Am. J. Obstet. Gynecol.167(2), 327–330 (1992).
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, Cockburn HA, Boralessa H, Contreras M. Which groups of patients are transfused? A study of red cell usage in London and southeast England. Vox Sang.83(4), 352–357 (2002).
   PubMed Web of Science ®Google Scholar
• Chiavetta JA, Herst R, Freedman J et al. A survey of red cell use in 45 hospitals in central Ontario, Canada. Transfusion36(8), 699–706 (1996).
   PubMed Web of Science ®Google Scholar
• Silverman JA, Barrett J, Callum JL. The appropriateness of red blood cell transfusions in the peripartum patient. Obstet. Gynecol.104(5 Pt 1), 1000–1004 (2004).
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective. Crit. Care10(4), R120 (2006).
   Web of Science ®Google Scholar
• Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology100(3), 722–730 (2004).
   PubMed Web of Science ®Google Scholar
• Mittal S, Watson HG. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br. J. Haematol.133(4), 355–363 (2006).
   PubMed Web of Science ®Google Scholar
• Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J. Clin. Invest.71(6), 1836–1841 (1983).
   PubMed Web of Science ®Google Scholar
• Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul. Fibrinolysis1(3), 307–317 (1990).
   PubMedGoogle Scholar
• Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood104(13), 3858–3864 (2004).
   PubMed Web of Science ®Google Scholar
• Thim L, Bjoern S, Christensen M et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry27(20), 7785–7793 (1988).
   PubMed Web of Science ®Google Scholar
• Bjoern S, Foster DC, Thim L et al. Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine. J. Biol. Chem.266(17), 11051–11057 (1991).
   PubMed Web of Science ®Google Scholar
• Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin. Pharmacol. Ther.55(6), 638–648 (1994).
   PubMed Web of Science ®Google Scholar
• Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin. Thromb. Hemost.26(4), 385–391 (2000).
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J. Thromb. Haemost.3(4), 640–648 (2005).
   PubMed Web of Science ®Google Scholar
• MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion45(9), 1434–1442 (2005).
   PubMed Web of Science ®Google Scholar
• Pieri P, Stein DM, Scarpelini S, Rizoli S. Pro/con debate: does recombinant factor VIIa have a role to play in the treatment of patients with acute nontraumatic hemorrhage? Crit. Care10(3), 214 (2006).
   PubMedGoogle Scholar
• Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology123(1), 118–126 (2002).
   PubMed Web of Science ®Google Scholar
• Bosch J, Thabut D, Bendtsen F et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology127(4), 1123–1130 (2004).
   PubMed Web of Science ®Google Scholar
• Planinsic RM, van der Meer J, Testa G et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl.11(8), 895–900 (2005).
   PubMed Web of Science ®Google Scholar
• Lodge JP, Jonas S, Oussoultzoglou E et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology102(2), 269–275 (2005).
   PubMed Web of Science ®Google Scholar
• Shao YF, Yang JM, Chau GY et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am. J. Surg.191(2), 245–249 (2006).
   PubMed Web of Science ®Google Scholar
• Boffard KD, Riou B, Warren B et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J. Trauma59(1), 8–15 (2005).
   PubMed Web of Science ®Google Scholar
• Diprose P, Herbertson MJ, O’Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br. J. Anaesth.95(5), 596–602 (2005).
   PubMed Web of Science ®Google Scholar
• Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N. Engl. J. Med.352(8), 777–785 (2005).
   PubMed Web of Science ®Google Scholar
• Friederich PW, Henny CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet361(9353), 201–205 (2003).
   PubMed Web of Science ®Google Scholar
• Scarpelini S, Rizoli S. Recombinant factor VIIa and the surgical patient. Curr. Opin. Crit. Care12(4), 351–356 (2006).
   PubMed Web of Science ®Google Scholar
• Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J. Thromb. Haemost.2(6), 899–909 (2004).
   PubMed Web of Science ®Google Scholar
• Verre M, Bossio F, Mammone A et al. Use of recombinant activated factor VII in a case of severe postpartum haemorrhage. Minerva Ginecol.58(1), 81–84 (2006).
   PubMedGoogle Scholar
• Hollnberger H, Gruber E, Seelbach-Goebel B. Major post-partum hemorrhage and treatment with recombinant factor VIIa. Anesth. Analg.101(6), 1886–1887 (2005).
   PubMed Web of Science ®Google Scholar
• Tanchev S, Platikanov V, Karadimov D. Administration of recombinant factor VIIa for the management of massive bleeding due to uterine atonia in the post-placental period. Acta Obstet. Gynecol. Scand.84(4), 402–403 (2005).
   PubMed Web of Science ®Google Scholar
• Shamsi TS, Hossain N, Soomro N et al. Use of recombinant factor VIIa for massive postpartum haemhorrage: case series and review of literature. J. Pak. Med. Assoc.55(11), 512–515 (2005).
   PubMedGoogle Scholar
• Boehlen F, Morales MA, Fontana P et al. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. Br. J. Obstet. Gynaecol.111(3), 284–287 (2004).
   Google Scholar
• Merchant SH, Mathew P, Vanderjagt TJ, Howdieshell TR, Crookston KP. Recombinant factor VIIa in management of spontaneous subcapsular liver hematoma associated with pregnancy. Obstet. Gynecol.103(5 Pt 2), 1055–1058 (2004).
   PubMed Web of Science ®Google Scholar
• Gidiri M, Noble W, Rafique Z, Patil K, Lindow SW. Caesarean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation factor VIIa. J. Obstet. Gynaecol.24(8), 925–926 (2004).
   PubMedGoogle Scholar
• Lim Y, Loo CC, Chia V, Fun W. Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy. Int. J. Gynaecol. Obstet.87(2), 178–179 (2004)
   PubMed Web of Science ®Google Scholar
• Price G, Kaplan J, Skowronski G. Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post-partum patient. Br. J. Anaesth.93(2), 298–300 (2004).
   PubMed Web of Science ®Google Scholar
• Segal S, Shemesh IY, Blumental R et al. The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet. Gynecol. Scand.83(8), 771–772 (2004).
   PubMed Web of Science ®Google Scholar
• Dart BW, Cockerham WT, Torres C, Kipikasa JH, Maxwell RA. A novel use of recombinant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndrome. J. Trauma57(1), 171–174 (2004).
   PubMedGoogle Scholar
• Bouwmeester FW, Jonkhoff AR, Verheijen RH, van Geijn HP. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet. Gynecol.101(6), 1174–1176 (2003).
   PubMed Web of Science ®Google Scholar
• Segal S, Shemesh IY, Blumenthal R et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch. Gynecol. Obstet.268(4), 266–267 (2003).
   PubMedGoogle Scholar
• Zupancic SS, Sokolic V, Viskovic T et al. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol.108(3), 162–163 (2002).
   Google Scholar
• Moscardo F, Perez F, de la Rubia J et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br. J. Haematol.114(1), 174–176 (2001).
   PubMed Web of Science ®Google Scholar
• Danilos J, Goral A, Paluszkiewicz P, Przesmycki K, Kotarski J. Successful treatment with recombinant factor VIIa for intractable bleeding at pelvic surgery. Obstet. Gynecol.101(6), 1172–1173 (2003).
   PubMed Web of Science ®Google Scholar
• Sajdak S, Moszynski R, Opala T. Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII. Eur. J. Gynaecol. Oncol.23(4), 325–326 (2002).
   PubMed Web of Science ®Google Scholar
• Clark AD, Gordon WC, Walker ID, Tait RC. ‘Last-ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang.86(2), 120–124 (2004).
   PubMed Web of Science ®Google Scholar
• Dutton RP, McCunn M, Hyder M et al. Factor VIIa for correction of traumatic coagulopathy. J. Trauma.57(4), 709–718 (2004).
   PubMed Web of Science ®Google Scholar
• Klitgaard T, Tabanera YP, Boffard K et al. Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit. Care10(4), R104 (2006).
   PubMedGoogle Scholar